First FDA-Approved Device for Emphysema Proven to Help Patients Breathe Easier and Enjoy More Active Lives
The Zephyr Endobronchial Valve is proven to help patients breathe easier and enjoy more active lives. (Graphic: Business Wire)
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx® Corp. announced today that the U.S. Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients. The Zephyr Valve is the first minimally-invasive device approved in the United States for treating patients with severe emphysema, a progressive and life-threatening form of chronic obstructive pulmonary disease (COPD).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180629005666/en/
Chronic Communications, Inc.